Xyphos Biosciences and Gladstone Institutes Announce Publication Demonstrating convertibleCAR® Cells and Bispecific Broadly Neutralizing Antibodies Reduce Latent HIV Reservoir

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Xyphos Biosciences, Inc. and Gladstone Institutes today announced the publication of key preclinical data demonstrating that convertibleCAR® cells attack and significantly reduce latent reservoirs of diverse HIV strains. These latent reservoirs persist even in patients taking antiretroviral therapy (ART) and are a major barrier to a cure for HIV/AIDS. The publication, “Attacking Latent HIV with convertibleCAR cells, a Highly Adaptable Killing Platfo

Click to view original post